• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis of Topical TXA to Reduce Surgical Blood Loss

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Tranexamic acid (TXA) is used to reduce blood loss and transfusion perioperatively
    • Topical administration of TXA has been studied, but its safety and efficacy are still unclear
  • Teoh et al. (Annals of Surgery, 2020) performed a review to assess the effect of topical TXA on incidence of blood transfusion and mortality in adults undergoing surgery

METHODS:

  • Systematic review and meta-analysis
  • Data sources
  • EMBASE, MEDLINE, CENTRAL, and ISI Web of Science Inclusion criteria
  • Study inclusion requirements
    • Parallel-arm RCTs

RESULTS:

  • Total 71 trials | Combined total of 7539 participants
    • Orthopedic participants: 5450
    • Nonorthopedic including gyn: 1909
  • Risk of bias assessment for all included studies
    • Low: 20 studies
    • Unclear: 26 studies
    • High: 25 studies
  • Variation in dosing and route
    • Dosage of topical TXA: 0.5 g to 3.0 g of TXA in 20 to 400mL of normal saline
    • Application route: Wound irrigation and spraying | Gyn studies included applying a soaked sponge onto the operative site or wound irrigation
  • When compared to placebo, topical TXA significantly reduced
    • Intraoperative blood loss: Mean difference (MD) -36.83 mL (95% CI, -54.77 to -18.88; P<0.001)
    • Total blood loss: MD -319.55 mL (95% CI, -387.42 to -251.69; P<0.001)
    • Incidence of blood transfusion: Odds ratio (OR) 0.30 (95% CI 0.26 to 0.34; P<0.001)
  • Topical TXA were associated with a shorter length of hospital stay
    • MD -0.28 days (95% CI, -0.47 to -0.08; P = 0.006)
  • The following adverse events were not associated with topical TXA
    • Mortality: P=0.39
    • Pulmonary embolism: P=0.52
    • DVT: P=0.79
    • Myocardial infarction: P=0.73
    • Stroke: P = 0.77

CONCLUSION:

  • Topical TXA was associated with a decrease in intraoperative blood loss, total blood loss | Blood transfusion was reduced by 70%
  • TXA dose and route varied | However, previous studies did not find TXA effect to be dose dependent
  • Mortality was not affected
    • However, authors note that larger numbers may be required To detect differences in mortality
    • Mortality is at higher risk for confounding due to various comorbidities and other factors
  • No adverse effects related to the use of topical TXA were observed

Learn More – Primary Sources:

Prophylactic Topical Tranexamic Acid Versus Placebo in Surgical Patients: A Systematic Review and Meta-Analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Tranexamic Acid Reduce Blood Loss During Myomectomy?
Results From the Landmark Trial on Tranexamic Acid for Postpartum Hemorrhage
How does TXA Measure Up as a Treatment for Menorrhagia?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site